BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Downgraded by Zacks Investment Research to Sell

Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a hold rating to a sell rating in a research note published on Tuesday, June 27th.

According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “

A number of other research analysts have also recently weighed in on BCRX. Noble Financial reiterated a buy rating on shares of BioCryst Pharmaceuticals in a research report on Saturday, May 6th. Jefferies Group LLC boosted their price objective on shares of BioCryst Pharmaceuticals from $3.50 to $6.00 and gave the company a positive rating in a research report on Tuesday, February 28th. HC Wainwright reaffirmed a buy rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, March 1st. Finally, Needham & Company LLC reissued a hold rating on shares of BioCryst Pharmaceuticals in a research report on Friday, May 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $8.29.

Shares of BioCryst Pharmaceuticals (BCRX) opened at 5.67 on Tuesday. The stock has a 50 day moving average of $5.65 and a 200-day moving average of $6.50. BioCryst Pharmaceuticals has a 52 week low of $2.86 and a 52 week high of $9.25. The stock’s market cap is $455.98 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.01. BioCryst Pharmaceuticals had a negative net margin of 150.24% and a negative return on equity of 323.86%. The company had revenue of $9.40 million for the quarter, compared to analysts’ expectations of $6.13 million. During the same quarter in the previous year, the business posted ($0.31) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 95.8% on a year-over-year basis. Equities research analysts predict that BioCryst Pharmaceuticals will post ($0.73) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://transcriptdaily.com/2017/07/18/biocryst-pharmaceuticals-inc-bcrx-downgraded-to-sell-at-zacks-investment-research-updated-updated.html.

Institutional investors have recently modified their holdings of the company. Fox Run Management L.L.C. acquired a new position in shares of BioCryst Pharmaceuticals during the second quarter valued at $126,000. Credit Suisse AG increased its position in shares of BioCryst Pharmaceuticals by 71.5% in the first quarter. Credit Suisse AG now owns 110,837 shares of the biotechnology company’s stock valued at $931,000 after buying an additional 46,204 shares during the period. Metropolitan Life Insurance Co. NY increased its position in shares of BioCryst Pharmaceuticals by 5.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 60,126 shares of the biotechnology company’s stock valued at $505,000 after buying an additional 3,339 shares during the period. Gotham Asset Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at $1,063,000. Finally, Highbridge Capital Management LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter valued at approximately $572,000. Institutional investors own 84.48% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply